Drug Profile
Research programme: malaria vaccine - Cytos/WRAIR
Latest Information Update: 13 May 2014
Price :
$50
*
At a glance
- Originator Cytos Biotechnology; Walter Reed Army Institute of Research
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Malaria
Most Recent Events
- 13 May 2014 Research programme: malaria vaccine - Cytos/WRAIR is available for licensing as of 05 May 2014. http://www.cytos.com
- 18 Aug 2011 Suspended for Malaria in USA (unspecified route)
- 31 Mar 2011 Early research in Malaria in USA (unspecified route)